Christian Rohrig

Director Of Operations at MICREOS - Den Haag, Zuid Holla, NL

Christian Rohrig's Colleagues at MICREOS
Marina Esposito

Project Management Manager- NPD Gladskin

Contact Marina Esposito

Ronald Eimers

Director Chemistry, Manufacturing and Control

Contact Ronald Eimers

Dominique Meijer

Scientist Drug Substance Development

Contact Dominique Meijer

Bob Rooij

Director Pre-Clinical Operations

Contact Bob Rooij

Maurice Selman

Analytical Method Development Lead

Contact Maurice Selman

View All Christian Rohrig's Colleagues
Christian Rohrig's Contact Details
HQ
N/A
Location
Zurich,Zurich,Switzerland
Company
MICREOS
Christian Rohrig's Company Details
MICREOS logo, MICREOS contact details

MICREOS

Den Haag, Zuid Holla, NL • 100 - 249 Employees
BioTech/Drugs

According to the World Health Organization (WHO) emergence of antibiotic-resistant 'superbugs' is now a global concern, which can spell the end of modern medicine and a return to the days when routine operations, simple wounds or straightforward infections were potentially life-threatening. On the other hand scientists have come to realize that the vast majority of bacteria is beneficial and should be left intact. Antibiotics do not distinguish between bad and good bacteria and their use can lead to side effects and resistance. Micreos develops the world's first targeted antibacterial products, set to replace antibiotics. With Micreos' endolysin technology, for the first time it is possible to kill only the unwanted bacteria - including antibiotic resistant strains such as MRSA - while leaving our microbiome - comprising billions of beneficial bacteria on our skin and in our gut - intact. In addition, research shows that the use of endolysins does not induce resistance. This unlocks a completely new approach in dealing with the bacteria around us: killing the bad bacteria and preserving the microbiome. Micreos' Staphefekt SA.100 is an enzyme (endolysin), that targets only Staphylococcus aureus. Marketed under the Gladskin brand, it is the world's first endolysin registered for human use and has had a life-changing impact for thousands of people suffering from inflammatory skin conditions such as eczema, inflammatory acne and rosacea and resistant wound infections (see www.gladskin.com). A series of pharmaceutical products based on the endolysin XZ.700 - also targeting S. aureus - is in clinical development. First indications include: atopic dermatitis, diabetic wound infections and folliculitis. Micreos has also developed FDA-approved food safety products: 'Phageguard S' against Salmonella and 'Phageguard L' against Listeria monocytogenes, which is especially dangerous for pregnant women and for the elderly and immuno-compromised (www.phageguard.com).

Research & Development Product introduction World class phage production Contract manufacturing Phage Technology Endolysin Technology Phage production Endolysin Production Microbiome Staphylococcus aureus MRSA Human Health Dermatology Eczema Rosacea Acne Folliculitis Diabetic Wound Infections Food Safety Listeria Salmonella Intracellular Staph Phageguard Gladskin
Details about MICREOS
Frequently Asked Questions about Christian Rohrig
Christian Rohrig currently works for MICREOS.
Christian Rohrig's role at MICREOS is Director Of Operations.
Christian Rohrig's email address is ***@micreos.com. To view Christian Rohrig's full email address, please signup to ConnectPlex.
Christian Rohrig works in the Research industry.
Christian Rohrig's colleagues at MICREOS are Marina Esposito, Ronald Eimers, Marloes Hagen, Dominique Meijer, Bob Rooij, Maurice Selman, Fabienne Arn and others.
Christian Rohrig's phone number is N/A
See more information about Christian Rohrig